Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 1/20 | 0.48 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 4/20 | 0.43 |
| ▸ | BRD4 | O60885 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.41 |
| ▸ | AXL | P30530 | 2/20 | 0.41 |
| ▸ | F11 | P03951 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26758147 | 0.84 | MEN1 (0.49) | ABCC1HPGDSMN1; SMN2POLB | |
| SCHEMBL24166099 | 0.84 | ABCC1 (0.48) | ABCC1HPGDBRD4ALDH1A1KDM4E | |
| SCHEMBL30656824 | 0.84 | ABCC1 (0.48) | ABCC1HPGDBRD4ALDH1A1KDM4E | |
| SCHEMBL30656830 | 0.83 | ALDH1A1 (0.56) | ABCC1HPGDALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL30656831 | 0.83 | MAPT (0.50) | ABCC1HPGDALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL24166887 | 0.83 | MAPT (0.50) | ABCC1HPGDALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL24166875 | 0.83 | ALDH1A1 (0.56) | ABCC1HPGDALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL30656829 | 0.82 | MAPT (0.52) | ABCC1HPGDALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL24166087 | 0.82 | MAPT (0.52) | ABCC1HPGDALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL24166490 | 0.81 | ALDH1A1 (0.60) | ABCC1HPGDBRD4ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357165-A1 | QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2023-11-09 | — | — | US | disclosed |
| US-20230357165-A1 | QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2023-11-09 | — | — | US | disclosed |
| WO-2022003712-A1 | QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2022-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357165-A1 | QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF | ATG7, GOT1, LIPC | MET 3093/4885ABCC1 1802/4885HPGD 2422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.